Figure 2.
PFS and OS with single-agent ibrutinib treatment. (A) PFS in the total efficacy population and by prior line of therapy. (B) OS in the total efficacy population and by prior line of therapy.

PFS and OS with single-agent ibrutinib treatment. (A) PFS in the total efficacy population and by prior line of therapy. (B) OS in the total efficacy population and by prior line of therapy.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal